Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-06-02

Clinical Trial Update: Tocilizumab for the Treatment of Behcet's Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating tocilizumab for Behçet's disease was terminated early. Results were posted on 2016-06-02.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tocilizumab (tocilizumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Behcet Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2016-06-02